tetano
Editor, Senior Moderator
J Med Virol
. 2021 Feb 16.
doi: 10.1002/jmv.26880. Online ahead of print.
Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19
Hatem Elalfy[SUP] 1 [/SUP], Tarek Besheer[SUP] 2 [/SUP], Ahmed El-Mesery[SUP] 3 [/SUP], Abdel-Hady El-Gilany[SUP] 4 [/SUP], Mahmoud Soliman Abd Elazez[SUP] 5 [/SUP], Ahmed Alhawarey[SUP] 5 [/SUP], Mohamed Alegezy[SUP] 6 [/SUP], Tamer Elhadidy[SUP] 7 [/SUP], Asem A Hewidy[SUP] 8 [/SUP], Hossam Zaghloul[SUP] 9 [/SUP], Mustafa Ahmed Mohamed Neamatallah[SUP] 10 [/SUP], Douaa Raafat[SUP] 9 [/SUP], Wafaa M El-Emshaty[SUP] 9 [/SUP], Nermin Y Abo El Kheir[SUP] 9 [/SUP], Mahmoud El-Bendary[SUP] 11 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic is caused by the novel Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan China. The urgent need for a safe and effective treatment has encouraged the researchers to initiate clinical trials evaluating the efficacy of many drugs targeting virus.
Aim: This trial compared the rate and time of viral clearance in subjects receiving the combination of nitazoxanide, ribavirin and ivermectin plus Zinc vs. those receiving supportive treatment.
Subject and methods: This non-randomized controlled trial included 62 patients on triple combination treatment versus 51 age- and sex-matched patients on routine supportive treatment.all of them confirmed case by positive RT-PCR of nasopharyngeal swab.
Results: Trial results showed that the clearance rates were 0% and 58.1% at 7th day and 13.7% and 73.1% at the 15th day in supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates at 15th day are 13.7 and 88.7% in supportive treatment and combined antiviral groups, respectively.
Conclusion: This trial concluded that combined use of Nitazoxanide, Ribavirin, and Ivermectin plus zinc supplement effectively clear the SARS-COV2 from nasopharynx in shorter time than the symptomatic therapy. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; antiviral; mild cases.
. 2021 Feb 16.
doi: 10.1002/jmv.26880. Online ahead of print.
Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19
Hatem Elalfy[SUP] 1 [/SUP], Tarek Besheer[SUP] 2 [/SUP], Ahmed El-Mesery[SUP] 3 [/SUP], Abdel-Hady El-Gilany[SUP] 4 [/SUP], Mahmoud Soliman Abd Elazez[SUP] 5 [/SUP], Ahmed Alhawarey[SUP] 5 [/SUP], Mohamed Alegezy[SUP] 6 [/SUP], Tamer Elhadidy[SUP] 7 [/SUP], Asem A Hewidy[SUP] 8 [/SUP], Hossam Zaghloul[SUP] 9 [/SUP], Mustafa Ahmed Mohamed Neamatallah[SUP] 10 [/SUP], Douaa Raafat[SUP] 9 [/SUP], Wafaa M El-Emshaty[SUP] 9 [/SUP], Nermin Y Abo El Kheir[SUP] 9 [/SUP], Mahmoud El-Bendary[SUP] 11 [/SUP]
Affiliations
- PMID: 33590901
- DOI: 10.1002/jmv.26880
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic is caused by the novel Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in Wuhan China. The urgent need for a safe and effective treatment has encouraged the researchers to initiate clinical trials evaluating the efficacy of many drugs targeting virus.
Aim: This trial compared the rate and time of viral clearance in subjects receiving the combination of nitazoxanide, ribavirin and ivermectin plus Zinc vs. those receiving supportive treatment.
Subject and methods: This non-randomized controlled trial included 62 patients on triple combination treatment versus 51 age- and sex-matched patients on routine supportive treatment.all of them confirmed case by positive RT-PCR of nasopharyngeal swab.
Results: Trial results showed that the clearance rates were 0% and 58.1% at 7th day and 13.7% and 73.1% at the 15th day in supportive treatment and combined antiviral groups, respectively. The cumulative clearance rates at 15th day are 13.7 and 88.7% in supportive treatment and combined antiviral groups, respectively.
Conclusion: This trial concluded that combined use of Nitazoxanide, Ribavirin, and Ivermectin plus zinc supplement effectively clear the SARS-COV2 from nasopharynx in shorter time than the symptomatic therapy. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; antiviral; mild cases.